Valneva (NASDAQ:VALN) Shares Gap Up - Here's Why

Valneva SE Sponsored ADR (NASDAQ:VALN - Get Free Report) shares gapped up before the market opened on Tuesday . The stock had previously closed at $6.08, but opened at $6.53. Valneva shares last traded at $6.54, with a volume of 7,799 shares.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on VALN shares. HC Wainwright reiterated a "buy" rating and set a $17.00 price objective on shares of Valneva in a research report on Tuesday, April 15th. Guggenheim decreased their price objective on shares of Valneva from $15.00 to $14.00 and set a "buy" rating for the company in a research report on Thursday, May 8th.

Valneva Price Performance

The company has a debt-to-equity ratio of 0.92, a current ratio of 2.70 and a quick ratio of 2.12. The firm has a market capitalization of $547.13 million, a price-to-earnings ratio of -5.40 and a beta of 1.74. The business's fifty day simple moving average is $6.10 and its 200 day simple moving average is $6.25.

Valneva (NASDAQ:VALN - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.13) EPS for the quarter, topping analysts' consensus estimates of ($0.40) by $0.27. The business had revenue of $51.79 million during the quarter, compared to analysts' expectations of $41.80 million. Valneva had a negative net margin of 43.08% and a negative return on equity of 43.05%. On average, research analysts forecast that Valneva SE Sponsored ADR will post 0.13 EPS for the current year.

Institutional Investors Weigh In On Valneva

A hedge fund recently bought a new stake in Valneva stock. GAMMA Investing LLC acquired a new stake in Valneva SE Sponsored ADR (NASDAQ:VALN - Free Report) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 13,964 shares of the company's stock, valued at approximately $94,000. 11.39% of the stock is owned by institutional investors and hedge funds.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.